|Bid||52.90 x 1800|
|Ask||53.05 x 1000|
|Day's Range||52.61 - 53.36|
|52 Week Range||36.15 - 64.94|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||55.77|
|Forward Dividend & Yield||1.40 (2.64%)|
|Ex-Dividend Date||Aug 13, 2020|
|1y Target Est||60.63|
Dr. Hilary Babcock, Professor of Medicine in the Infectious Diseases division at Washington University School of Medicine joins Yahoo Finance's Kristin Myers to discuss the latest coronavirus developments as U.S. hospitalizations reach an all time high.
Coronavirus vaccines offer an interesting growth opportunity for investors, but there are factors that investors should consider before jumping into the space. In this video from Motley Fool Live recorded on Nov. 23, Corinne Cardina, chief of Motley Fool's healthcare and cannabis bureau, and Brian Orelli, Fool.com contributor, discuss how the durability of immunity, which is largely unknown at this point, factors into valuation. Corinne Cardina: Let's talk a little bit about the partnership with the University of Oxford and who is going to get this particular vaccine candidate if it is approved and comes to fruition.
Assessments from the EU's drug regulator on two of the leading coronavirus vaccine candidates won’t come for about a month, putting the 27 member countries behind the U.S. and U.K. in mobilizing for widespread vaccinations.